An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations

Overview of attention for article published in Science Translational Medicine, March 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

So far, Altmetric has seen 559 X posts from 482 X users, with an upper bound of 6,719,818 followers.

RT @michaelzlin: Pleased to report, at long last, the publication of ML2006a4, our SARS-CoV-2 protease inhibitor for COVID-19, in @ScienceT…

RT @michaelzlin: Pleased to report, at long last, the publication of ML2006a4, our SARS-CoV-2 protease inhibitor for COVID-19, in @ScienceT…

RT @ScienceMagazine: An antiviral for #SARSCoV2 based on the hepatitis C drug boceprevir matches the performance of approved drugs like #ni…

RT @EricTopol: "Drug design at the atomic level" vs Covid Report of a new oral drug vs #SARSCoV2 which is more potent and less sensitive to…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 555 additional X posts.